Stefania Canova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefania Canova has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Diego Cortinovis
Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori di Monza, Monza, Italy; Department of Clinical Medicine, University of Milano-Bicocca, Monza, Italy
3 shared publications Alberto Bernardi
University of Siena ()
1 shared publicationAlfredo Addeo
Oncology Department, University Hospital Geneva, 1205 Geneva, Switzerland
1 shared publicationAntonio Russo
Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Italy
1 shared publication- Federico Ambrogi
Scientific Directorate, IRCCS Policlinico San Donato , San Donato Milanese, 20097, Milan
1 shared publication Francesca Colonese
Medical Oncology Unit, San Gerardo Hospital, Monza, Italy
1 shared publication
Latest Publications
- Open Access
- 3 December 2021
- Published by IMR Press in Frontiers in Bioscience-Scholar
- Vol. 13 (2) , 190-201
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer
Squamous cell lung cancer (SqCLC) is the second most common histotype of non-small cell lung cancer (NSCLC) and is characterized by severe prognosis and lack of specific target agents. Atezolizumab is the first anti Programmed Death Ligand-1 (PDL-1) inhibitor approved for NSCLC patients of both histology in case of disease progression after first or further lines of therapy. Numerous studies are investigating the potential role of atezolizumab in different therapeutic setting, including SqCLC subtype. We searched for published clinical trials in Pubmed database, using the terms “atezolizumab”, “squamous cell lung cancer”, “NSCLC” and “non-small cell lung cancer”. We also searched for recently concluded and not yet published or ongoing trials in clinicaltrials.gov and in data from the latest international congresses. The aim of this review is to summarize current evidence on atezolizumab in SqCLC, from first line setting to novel potential indications from ongoing trials. Strengths and weaknesses of atezolizumab treatment were highlighted to speculate the role of this immune checkpoint inhibitor in novel future clinical scenarios.
- 3 December 2021
- Published by IMR Press in Frontiers in Bioscience-Scholar
- Vol. 13 (2) , 190-201
Open AccessAnti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer
Squamous cell lung cancer (SqCLC) is the second most common histotype of non-small cell lung cancer (NSCLC) and is characterized by severe prognosis and lack of specific target agents. Atezolizumab is the first anti Programmed Death Ligand-1 (PDL-1) inhibitor approved for NSCLC patients of both histology in case of disease progression after first or further lines of therapy. Numerous studies are investigating the potential role of atezolizumab in different therapeutic setting, including SqCLC subtype. We searched for published clinical trials in Pubmed database, using the terms “atezolizumab”, “squamous cell lung cancer”, “NSCLC” and “non-small cell lung cancer”. We also searched for recently concluded and not yet published or ongoing trials in clinicaltrials.gov and in data from the latest international congresses. The aim of this review is to summarize current evidence on atezolizumab in SqCLC, from first line setting to novel potential indications from ongoing trials. Strengths and weaknesses of atezolizumab treatment were highlighted to speculate the role of this immune checkpoint inhibitor in novel future clinical scenarios.
- 1 September 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 129, 27-39
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
- 1 September 2018
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 129, 27-39
Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection
- Open Access
- 1 June 2017
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 9 (6) , 1741-1743
How to describe univariate data
Univariate analysis has the purpose to describe a single variable distribution in one sample. It is the first important step of every clinical trial. In this short review, we focus on this analysis, the methods that authors should use to report this type of data, information that they should not miss and mistakes that they must avoid.
- 1 June 2017
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 9 (6) , 1741-1743
Open AccessHow to describe univariate data
Univariate analysis has the purpose to describe a single variable distribution in one sample. It is the first important step of every clinical trial. In this short review, we focus on this analysis, the methods that authors should use to report this type of data, information that they should not miss and mistakes that they must avoid.